Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Chronic Myeloid Leukemia

August 8, 2017

Join Jerald P. Radich, MD and Cecelia Yeung, MD from Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance as they present their expertise on a range of cases pertaining to chronic myeloid leukemia (CML).

CML is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation [t(9;22] that gives rise to a BCR-ABL1 fusion gene. Tyrosine kinase inhibitor (TKI) therapy with small molecule inhibitors of BCR-ABL tyrosine kinase has significantly reduced the annual mortality rate among patients with chronic phase CML (CP-CML). The goal of TKI therapy is to achieve complete cytogenetic response (CCyR) within 12 months of TKI therapy and to prevent disease progression. In patients achieving CCyR, CML is now managed like a chronic disease, requiring long-term treatment and supportive care.

A better understanding of the safety and efficacy profile of TKIs, the importance of molecular monitoring, and the significance of response milestones is essential to provide optimal long-term care for patients with CP-CML. Patient education on adherence to TKI therapy and close monitoring of patient’s adherence are critical to achieving early response milestones. Clinicians need to have up-to-date information to appropriately select and monitor these patients.

Target Audience

This educational program is designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, case managers, and other health care professionals who manage patients with cancer.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • Astellas and Medivation, Inc., a Pfizer Company
  • AstraZeneca
  • Lilly
  • Takeda Oncology

This activity is supported by independent educational grants from:

  • AbbVie
  • Boehringer Ingelheim Pharmaceuticals, Inc.

This educational activity is supported by a medical education grant from Exelixis, Inc.


Supporter list last updated on June 7, 2017.

Course summary
Available credit: 
  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
Course opens: 
08/08/2017
Course expires: 
10/01/2017
Event starts: 
08/08/2017 - 1:30pm
Event ends: 
08/08/2017 - 2:30pm
Cost:
$0.00

Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Cecelia Yeung, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

Physicians
National Comprehensive Cancer Network is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.0 hour of Category I credit for completing this activity.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. Credit approval for case managers is pending for this program. Pending approval, the activity code and approval number will be posted prior to the activity date.

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN will be posted prior to the activity date.

Available Credit

  • 1.00 CCM clock hours
  • 1.00 ACPE contact hours
  • 1.00 ANCC contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Select the appropriate first-line TKI therapy for patients with CP-CML based on the risk score, toxicity profile of TKI, and individual patient characteristics.
  • Review the toxicity profile of individual TKIs and identify the factors contributing to non-adherence to TKI.
  • Develop an optimal long-term treatment plan incorporating regular monitoring of molecular response and effective supportive care plan for the prevention and management of potential treatment-related side effects.

Accreditation Period

Course opens: 
08/08/2017
Course expires: 
10/01/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing